These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 19435491)
1. The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. Echouffo-Tcheugui JB; Simmons RK; Williams KM; Barling RS; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ BMC Public Health; 2009 May; 9():136. PubMed ID: 19435491 [TBL] [Abstract][Full Text] [Related]
2. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. Simmons RK; Borch-Johnsen K; Lauritzen T; Rutten GE; Sandbæk A; van den Donk M; Black JA; Tao L; Wilson EC; Davies MJ; Khunti K; Sharp SJ; Wareham NJ; Griffin SJ Health Technol Assess; 2016 Aug; 20(64):1-86. PubMed ID: 27583404 [TBL] [Abstract][Full Text] [Related]
3. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Simmons RK; Echouffo-Tcheugui JB; Sharp SJ; Sargeant LA; Williams KM; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ Lancet; 2012 Nov; 380(9855):1741-8. PubMed ID: 23040422 [TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Webb DR; Khunti K; Srinivasan B; Gray LJ; Taub N; Campbell S; Barnett J; Henson J; Hiles S; Farooqi A; Griffin SJ; Wareham NJ; Davies MJ Trials; 2010 Feb; 11():16. PubMed ID: 20170482 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. Griffin SJ; Rutten GEHM; Khunti K; Witte DR; Lauritzen T; Sharp SJ; Dalsgaard EM; Davies MJ; Irving GJ; Vos RC; Webb DR; Wareham NJ; Sandbæk A Lancet Diabetes Endocrinol; 2019 Dec; 7(12):925-937. PubMed ID: 31748169 [TBL] [Abstract][Full Text] [Related]
6. Protocol for the ADDITION-Plus study: a randomised controlled trial of an individually-tailored behaviour change intervention among people with recently diagnosed type 2 diabetes under intensive UK general practice care. Griffin SJ; Simmons RK; Williams KM; Prevost AT; Hardeman W; Grant J; Whittle F; Boase S; Hobbis I; Brage S; Westgate K; Fanshawe T; Sutton S; Wareham NJ; Kinmonth AL; BMC Public Health; 2011 Apr; 11():211. PubMed ID: 21463520 [TBL] [Abstract][Full Text] [Related]
7. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. Laxy M; Wilson ECF; Boothby CE; Griffin SJ Value Health; 2017 Dec; 20(10):1288-1298. PubMed ID: 29241888 [TBL] [Abstract][Full Text] [Related]
8. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Lauritzen T; Griffin S; Borch-Johnsen K; Wareham NJ; Wolffenbuttel BH; Rutten G; Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S6-11. PubMed ID: 11063279 [TBL] [Abstract][Full Text] [Related]
9. Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. Van den Donk M; Griffin SJ; Stellato RK; Simmons RK; Sandbæk A; Lauritzen T; Khunti K; Davies MJ; Borch-Johnsen K; Wareham NJ; Rutten GE Diabetologia; 2013 Aug; 56(11):2367-77. PubMed ID: 23959571 [TBL] [Abstract][Full Text] [Related]
10. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Charles M; Fleischer J; Witte DR; Ejskjaer N; Borch-Johnsen K; Lauritzen T; Sandbaek A Diabetologia; 2013 Jan; 56(1):101-8. PubMed ID: 23064291 [TBL] [Abstract][Full Text] [Related]
11. Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Gray LJ; Khunti K; Williams S; Goldby S; Troughton J; Yates T; Gray A; Davies MJ; Cardiovasc Diabetol; 2012 May; 11():56. PubMed ID: 22607160 [TBL] [Abstract][Full Text] [Related]
12. Does training of general practitioners for intensive treatment of people with screen-detected diabetes have a spillover effect on mortality and cardiovascular morbidity in 'at risk' individuals with normoglycaemia? Results from the ADDITION-Denmark cluster-randomised controlled trial. Simmons RK; Bruun NH; Witte DR; Borch-Johnsen K; Jørgensen ME; Sandbæk A; Lauritzen T Diabetologia; 2017 Jun; 60(6):1016-1021. PubMed ID: 28280901 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461 [TBL] [Abstract][Full Text] [Related]
14. Pharmacy Diabetes Screening Trial: protocol for a pragmatic cluster-randomised controlled trial to compare three screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Krass I; Carter R; Mitchell B; Mohebbi M; Shih STF; Trinder P; Versace VL; Wilson F; Namara KM BMJ Open; 2017 Dec; 7(12):e017725. PubMed ID: 29284715 [TBL] [Abstract][Full Text] [Related]
15. Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Sortsø C; Komkova A; Sandbæk A; Griffin SJ; Emneus M; Lauritzen T; Simmons RK Diabetologia; 2018 Jun; 61(6):1306-1314. PubMed ID: 29549417 [TBL] [Abstract][Full Text] [Related]
16. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Griffin SJ; Borch-Johnsen K; Davies MJ; Khunti K; Rutten GE; Sandbæk A; Sharp SJ; Simmons RK; van den Donk M; Wareham NJ; Lauritzen T Lancet; 2011 Jul; 378(9786):156-67. PubMed ID: 21705063 [TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
19. Screening for type 2 diabetes: literature review and economic modelling. Waugh N; Scotland G; McNamee P; Gillett M; Brennan A; Goyder E; Williams R; John A Health Technol Assess; 2007 May; 11(17):iii-iv, ix-xi, 1-125. PubMed ID: 17462167 [TBL] [Abstract][Full Text] [Related]